US EditionPublished • loading... • Updated
ASH 2025: J&J’s Tecvayli + Darzale set to redefine early relapse MM
Summary by Clinical Trials Arena
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
ASH 2025: J&J’s Tecvayli + Darzale set to redefine early relapse MM
The primary endpoint of PFS at a median follow-up of 34.5 months was significantly improved in the experimental arm with Darzalex + Tecvayli.The post ASH 2025: J&J’s Tecvayli + Darzale set to redefine early relapse MM appeared first on Clinical Trials Arena.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
